Ross McKinney

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021
    Ross E McKinney
    Department of Pediatrics, Duke University Medical Center, Box 3461, Durham, NC 27710, USA
    Pediatrics 120:e416-23. 2007
  2. pmc Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology?
    Ross McKinney
    Duke University School of Medicine, Durham, North Carolina, USA
    PLoS Med 2:e9. 2005
  3. ncbi request reprint Congress, the FDA, and the fair development of new medications for children
    Ross E McKinney
    Department of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA
    Pediatrics 112:669-70. 2003
  4. ncbi request reprint Newer treatments for HIV in children
    Ross E McKinney
    Departmentof Pedicatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Pediatr 16:76-9. 2004
  5. ncbi request reprint Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials
    Daniel K Benjamin
    Department of Pediatrics, Duke University, Durham, NC, USA
    J Antimicrob Chemother 54:701-3. 2004
  6. ncbi request reprint Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection
    Caroline J Chantry
    Department of Pediatrics, University of California Davis Medical Center, Sacramento 95817, USA
    Pediatr Infect Dis J 22:1033-9. 2003
  7. ncbi request reprint Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection
    Kumud K Singh
    Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, La Jolla, California 92093 0672, USA
    J Infect Dis 188:1461-72. 2003
  8. ncbi request reprint A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV
    Daniel K Benjamin
    Duke Clinical Research Institute and the Department of Pediatrics, Duke University, Durham, North Carolina, USA
    AIDS 17:2331-6. 2003
  9. ncbi request reprint Prevalence of chemokine and chemokine receptor polymorphisms in seroprevalent children with symptomatic HIV-1 infection in the United States
    Kumud K Singh
    Department of Pediatrics, Division of Infectious Diseases, University of California at San Diego, La Jolla 92093 0672, USA
    J Acquir Immune Defic Syndr 35:309-13. 2004
  10. ncbi request reprint Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children
    Edmund V Capparelli
    University of California, San Diego, School of Medicine, La Jolla, California, USA
    J Clin Pharmacol 43:133-40. 2003

Research Grants

  1. North Carolina Collaborative PPRU Network
    Ross McKinney; Fiscal Year: 2004
  2. Integrated Human Research Subjects Protection Project
    Ross McKinney; Fiscal Year: 2003

Detail Information

Publications11

  1. ncbi request reprint Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021
    Ross E McKinney
    Department of Pediatrics, Duke University Medical Center, Box 3461, Durham, NC 27710, USA
    Pediatrics 120:e416-23. 2007
    ..Compliance with complex antiretroviral therapy regimens is a problem for HIV-1-infected children and their families. Simple, safe, and effective regimens are important for long-term therapeutic success...
  2. pmc Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology?
    Ross McKinney
    Duke University School of Medicine, Durham, North Carolina, USA
    PLoS Med 2:e9. 2005
    ..Although this financial incentive can stimulate academic researchers to discover new drugs and devices, there is concern that the possibility of monetary reward could distort investigators' objectivity...
  3. ncbi request reprint Congress, the FDA, and the fair development of new medications for children
    Ross E McKinney
    Department of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA
    Pediatrics 112:669-70. 2003
  4. ncbi request reprint Newer treatments for HIV in children
    Ross E McKinney
    Departmentof Pedicatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Pediatr 16:76-9. 2004
    ..Several new antiretroviral agents have been introduced into pediatric and adult use. This review will summarize information about these new agents and other recent advances in the care of HIV-infected children...
  5. ncbi request reprint Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials
    Daniel K Benjamin
    Department of Pediatrics, Duke University, Durham, NC, USA
    J Antimicrob Chemother 54:701-3. 2004
    ....
  6. ncbi request reprint Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection
    Caroline J Chantry
    Department of Pediatrics, University of California Davis Medical Center, Sacramento 95817, USA
    Pediatr Infect Dis J 22:1033-9. 2003
    ..The relationships among weight and height growth, viral load and survival in HIV-infected children remain unclear...
  7. ncbi request reprint Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection
    Kumud K Singh
    Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, La Jolla, California 92093 0672, USA
    J Infect Dis 188:1461-72. 2003
    ..These data suggest that, in children, host genetics plays an important role in HIV-1-related disease progression and neurological impairment...
  8. ncbi request reprint A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV
    Daniel K Benjamin
    Duke Clinical Research Institute and the Department of Pediatrics, Duke University, Durham, North Carolina, USA
    AIDS 17:2331-6. 2003
    ..However, WAZ and height velocity (HAZ) have not been critically compared for their utility as part of the composite endpoint...
  9. ncbi request reprint Prevalence of chemokine and chemokine receptor polymorphisms in seroprevalent children with symptomatic HIV-1 infection in the United States
    Kumud K Singh
    Department of Pediatrics, Division of Infectious Diseases, University of California at San Diego, La Jolla 92093 0672, USA
    J Acquir Immune Defic Syndr 35:309-13. 2004
    ..These analyses show that the distribution of chemokine receptor and chemokine genetic polymorphisms varies significantly across race/ethnicity subgroups of HIV-1-infected children in the United States...
  10. ncbi request reprint Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children
    Edmund V Capparelli
    University of California, San Diego, School of Medicine, La Jolla, California, USA
    J Clin Pharmacol 43:133-40. 2003
    ..It was concluded that ZDV oral clearance is reduced in infants compared to older children. This lower clearance leads to higher ZDV exposure in infants and contributes to increased hematologic toxicity...
  11. ncbi request reprint Shooting at a moving target: natural history studies and the rapidly improving state of anti-HIV treatment
    Ross E McKinney
    J Pediatr 141:301-2. 2002

Research Grants2

  1. North Carolina Collaborative PPRU Network
    Ross McKinney; Fiscal Year: 2004
    ..6) To train physicians and pharmacologists in clinical and developmental pharmacology: the centerpiece will be a 3-year pediatric pharmacology fellowship. Drs. Brouwer and Lindley (UNC) will lead this program. ..
  2. Integrated Human Research Subjects Protection Project
    Ross McKinney; Fiscal Year: 2003
    ..abstract_text> ..